ZLAB and 1ZLB Related Headlines
Go Back- Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
- Zai Lab Announces Changes to Senior Leadership Team
- Zai Lab receives FDA fast track designation for cancer drug
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
- Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
- Zai Lab shares preclinical data for atopic dermatitis drug candidate
- Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
- Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Ne
- Zai Lab partners with Amgen for combination cancer therapy trial
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
- Zai Lab to present three oncology candidates at AACR 2026
- Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
- Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
- Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
- Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
- Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
- Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
- Zai Lab begins phase 1 trial of atopic dermatitis drug ZL-1503
- Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
- Zai Lab Announces Updates to China’s National Reimbursement Drug List
- Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in Investor Conferences in November and December 2025
- Zai Lab reports phase 1 data for small cell lung cancer drug candidate
- Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initia
- The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
- Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
- Zai Lab to present updated data on lung cancer drug at 2025 conference
- Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
- Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
- Zai Lab Announces Participation in Investor Conferences in September 2025
- Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
- Zai Lab forms oncology scientific advisory board
- Zai Lab Establishes Oncology Scientific Advisory Board
- Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
- Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
ZLAB and 1ZLB Related Press Releases
Go Back- Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
- Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
- Zai Lab Announces Changes to Senior Leadership Team
- Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
- Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
- Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
- Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Ne
- Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
- Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
- Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
- Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
- Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
- Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
- Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
- Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
- Zai Lab Announces Updates to China’s National Reimbursement Drug List
- Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
- Zai Lab Announces Participation in Investor Conferences in November and December 2025
- Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initia
- The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners
- Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
- Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
- Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
- Zai Lab Announces Participation in Investor Conferences in September 2025
- Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
- Zai Lab Establishes Oncology Scientific Advisory Board
- Zai Lab Announces Second Quarter 2025 Financial Results and Recent Corporate Updates
- Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
- Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
ZLAB and 1ZLB Related SEC Filings
Go Back- Form 8-K Zai Lab Ltd For: Jun 17
- Form SCHEDULE 13G Zai Lab Ltd Filed by: TCG Crossover GP II, LLC
- Form 8-K Zai Lab Ltd For: May 18
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Apr 06 Filed by: Edmondson Frazor Titus III
- Form 4 Zai Lab Ltd For: Apr 06 Filed by: Smiley Joshua L
- Form 4 Zai Lab Ltd For: Apr 06 Filed by: Amado Rafael
- Form 4 Zai Lab Ltd For: Apr 06 Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Apr 06 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Edmondson Frazor Titus III
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Smiley Joshua L
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Amado Rafael
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 17 Filed by: GAYNOR RICHARD
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Smiley Joshua L
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Edmondson Frazor Titus III
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Amado Rafael
- Form 4 Zai Lab Ltd For: Mar 11 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Smiley Joshua L
- Form 144 Zai Lab Ltd Filed by: Amado Rafael
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Mar 10 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 06 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 04 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 05 Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Mar 03 Filed by: Amado Rafael
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Amado Rafael
- Form 10-K Zai Lab Ltd For: Dec 31
- Form 8-K Zai Lab Ltd For: Feb 26
- Form SCHEDULE 13G Zai Lab Ltd Filed by: RTW INVESTMENTS, LP
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: Qiming Corporate GP IV, Ltd
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: Capital World Investors
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: WELLINGTON MANAGEMENT GROUP LLP
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: FMR LLC
- Form 4 Zai Lab Ltd For: Dec 30 Filed by: Amado Rafael
- Form 144 Zai Lab Ltd Filed by: Amado Rafael
- Form 4 Zai Lab Ltd For: Dec 16 Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 4 Zai Lab Ltd For: Dec 10 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Nov 21 Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: RTW INVESTMENTS, LP
- Form SCHEDULE 13G Zai Lab Ltd Filed by: WELLINGTON MANAGEMENT GROUP LLP
- Form 10-Q Zai Lab Ltd For: Sep 30
- Form 8-K Zai Lab Ltd For: Nov 06
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: FMR LLC
- Form 4 Zai Lab Ltd For: Oct 31 Filed by: Chen Yajing
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 8-K Zai Lab Ltd For: Oct 13
- Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Sep 10 Filed by: Smiley Joshua L
- Form 4 Zai Lab Ltd For: Aug 29 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Aug 15 Filed by: Edmondson Frazor Titus III
- Form 4 Zai Lab Ltd For: Aug 15 Filed by: Smiley Joshua L
- Form 4 Zai Lab Ltd For: Aug 14 Filed by: Chen Yajing
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Smiley Joshua L
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Aug 12 Filed by: Du Ying
- Form SCHEDULE 13G Zai Lab Ltd Filed by: RTW INVESTMENTS, LP
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Aug 08 Filed by: Amado Rafael
- Form 4 Zai Lab Ltd For: Aug 08 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Aug 08 Filed by: Chen Yajing
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: WELLINGTON MANAGEMENT GROUP LLP
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: Qiming Venture Partners IV, L.P.
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Amado Rafael
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 10-Q Zai Lab Ltd For: Jun 30
- Form 8-K Zai Lab Ltd For: Aug 07
- Form SCHEDULE 13G/A Zai Lab Ltd Filed by: FMR LLC
- Form 4 Zai Lab Ltd For: Jul 02 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Jul 01 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Jun 27 Filed by: Du Ying
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Jun 25 Filed by: Chen Yajing
- Form 4 Zai Lab Ltd For: Jun 25 Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Jun 25 Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Edmondson Frazor Titus III
- Form 144 Zai Lab Ltd Filed by: Chen Yajing
- Form 144 Zai Lab Ltd Filed by: Du Ying
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: Vounatsos Michel
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: WIRTH PETER
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: Leung Nisa
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: Lis William
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: DIEKMAN JOHN D
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: GAYNOR RICHARD
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: Morrison Scott W
- Form 4 Zai Lab Ltd For: Jun 18 Filed by: MOULDER LEON O JR
